The WIL-31 study showed that prophylaxis with wilate (a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio) is highly efficacious in reducing bleeding rates in adults and children with VWD of all types. The gene discussed is VWF; the disease is von Willebrand disease (hereditary or acquired).